This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2007 Sep 20;25(27):4157-8.

doi: 10.1200/JCO.2007.12.1723. Epub 2007 Aug 13.

Ovarian cancer: is dose intensity dead?

PMID: 17698802
DOI: 10.1200/JCO.2007.12.1723

Editorial

Ovarian cancer: is dose intensity dead?

Robert F Ozols. J Clin Oncol. 2007.

. 2007 Sep 20;25(27):4157-8.

doi: 10.1200/JCO.2007.12.1723. Epub 2007 Aug 13.

Author

PMID: 17698802
DOI: 10.1200/JCO.2007.12.1723

No abstract available

PubMed Disclaimer

Comment on

Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.
Möbus V, Wandt H, Frickhofen N, Bengala C, Champion K, Kimmig R, Ostermann H, Hinke A, Ledermann JA; AGO-Ovar/AIO; EBMT. Möbus V, et al. J Clin Oncol. 2007 Sep 20;25(27):4187-93. doi: 10.1200/JCO.2006.09.7527. Epub 2007 Aug 13. J Clin Oncol. 2007. PMID: 17698804 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information